Kala Pharmaceuticals, Inc. (KALA)
USD 3.75
(0.81%)
USD 3.75
(0.81%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 39.15 Million USD | -53.02% |
| 2022 | 82.68 Million USD | -29.07% |
| 2021 | 116.57 Million USD | 17.26% |
| 2020 | 99.42 Million USD | 7.73% |
| 2019 | 92.29 Million USD | 42.6% |
| 2018 | 64.72 Million USD | 62.31% |
| 2017 | 39.87 Million USD | 22.06% |
| 2016 | 32.66 Million USD | 104.3% |
| 2015 | 15.99 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 9.57 Million USD | -18.23% |
| 2024 Q1 | 11.7 Million USD | 26.28% |
| 2023 Q4 | 9.27 Million USD | -11.76% |
| 2023 FY | 38.85 Million USD | -53.02% |
| 2023 Q1 | 10.06 Million USD | 9.96% |
| 2023 Q2 | 9.24 Million USD | -8.21% |
| 2023 Q3 | 10.5 Million USD | 13.7% |
| 2022 Q4 | 9.15 Million USD | -38.73% |
| 2022 FY | 82.68 Million USD | -29.07% |
| 2022 Q2 | 27.14 Million USD | -13.68% |
| 2022 Q3 | 14.94 Million USD | -44.96% |
| 2022 Q1 | 31.44 Million USD | 18.94% |
| 2021 Q1 | 30.82 Million USD | 3.22% |
| 2021 Q3 | 28.23 Million USD | -9.17% |
| 2021 Q4 | 26.44 Million USD | -6.34% |
| 2021 FY | 116.57 Million USD | 17.26% |
| 2021 Q2 | 31.08 Million USD | 0.83% |
| 2020 FY | 99.42 Million USD | 7.73% |
| 2020 Q4 | 29.86 Million USD | 9.14% |
| 2020 Q3 | 27.36 Million USD | 28.13% |
| 2020 Q2 | 21.35 Million USD | 2.46% |
| 2020 Q1 | 20.84 Million USD | 1.03% |
| 2019 Q3 | 22.35 Million USD | -7.32% |
| 2019 Q2 | 24.11 Million USD | -4.29% |
| 2019 Q1 | 25.19 Million USD | 6.9% |
| 2019 FY | 92.29 Million USD | 42.6% |
| 2019 Q4 | 20.63 Million USD | -7.7% |
| 2018 Q2 | 14.51 Million USD | 30.34% |
| 2018 Q3 | 15.49 Million USD | 6.73% |
| 2018 FY | 64.72 Million USD | 62.31% |
| 2018 Q1 | 11.13 Million USD | -0.01% |
| 2018 Q4 | 23.56 Million USD | 52.09% |
| 2017 Q4 | 11.14 Million USD | 16.84% |
| 2017 Q1 | 9.57 Million USD | -4.15% |
| 2017 Q2 | 9.63 Million USD | 0.62% |
| 2017 Q3 | 9.53 Million USD | -1.0% |
| 2017 FY | 39.87 Million USD | 22.06% |
| 2016 Q4 | 9.98 Million USD | 2.44% |
| 2016 Q2 | 7.86 Million USD | 54.87% |
| 2016 FY | 32.66 Million USD | 104.3% |
| 2016 Q1 | 5.07 Million USD | 0.0% |
| 2016 Q3 | 9.74 Million USD | 23.99% |
| 2015 FY | 15.99 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 271.89 Million USD | 85.6% |
| Theratechnologies Inc. | 72.75 Million USD | 46.186% |
| Safety Shot Inc | 12.1 Million USD | -223.319% |
| Cosmos Health Inc. | 26.18 Million USD | -49.549% |
| Cronos Group Inc. | 96.7 Million USD | 59.515% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 83.133% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 87.536% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -182.858% |
| ProPhase Labs, Inc. | 37.85 Million USD | -3.437% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -314.493% |
| Dynavax Technologies Corporation | 219.14 Million USD | 82.134% |
| Radius Health, Inc. | 265.92 Million USD | 85.277% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -1175.679% |
| Alvotech | 285.43 Million USD | 86.283% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -198.321% |
| Alpha Teknova, Inc. | 45.85 Million USD | 14.623% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 93.364% |
| SCYNEXIS, Inc. | 51.84 Million USD | 24.485% |
| Harrow Health, Inc. | 89.97 Million USD | 56.484% |
| Biofrontera Inc. | 39.95 Million USD | 2.017% |
| DURECT Corporation | 43.71 Million USD | 10.436% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 92.599% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 80.022% |
| OptiNose, Inc. | 85.1 Million USD | 53.993% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 509.507% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | 12.71% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | 9.032% |
| SIGA Technologies, Inc. | 22.04 Million USD | -77.621% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | 20.158% |
| Shineco, Inc. | 17.94 Million USD | -118.146% |
| Phibro Animal Health Corporation | 260.29 Million USD | 84.958% |
| Procaps Group S.A. | 187.24 Million USD | 79.09% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -298.504% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -880.998% |
| Viatris Inc. | 5.96 Billion USD | 99.344% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -198.321% |
| Rockwell Medical, Inc. | 15.37 Million USD | -154.67% |
| Incannex Healthcare Limited | 30.05 Million USD | -30.28% |
| Aytu BioPharma, Inc. | 59.84 Million USD | 34.571% |
| Tilray Brands, Inc. | 251.35 Million USD | 84.423% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 75.408% |
| PetIQ, Inc. | 192.72 Million USD | 79.685% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -5034.874% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 97.548% |
| Journey Medical Corporation | 54.59 Million USD | 28.283% |
| Alimera Sciences, Inc. | 62.64 Million USD | 37.496% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -119.855% |
| Assertio Holdings, Inc. | 368.58 Million USD | 89.377% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -565.237% |
| Embecta Corp. | 528.4 Million USD | 92.59% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -86.07% |
| Procaps Group, S.A. | 199.47 Million USD | 80.372% |
| PainReform Ltd. | 9.58 Million USD | -308.525% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 76.266% |
| Hempacco Co., Inc. | 7.59 Million USD | -415.412% |
| Talphera, Inc. | 11.99 Million USD | -226.438% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 88.004% |
| Alvotech | 285.43 Million USD | 86.283% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 88.648% |
| Kamada Ltd. | 45.42 Million USD | 13.809% |
| Indivior PLC | 911 Million USD | 95.702% |
| Currenc Group, Inc. | 24 Million USD | -63.123% |
| Evoke Pharma, Inc. | 12.4 Million USD | -215.505% |
| Flora Growth Corp. | 10.57 Million USD | -270.101% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -86.07% |
| Evolus, Inc. | 189.75 Million USD | 79.367% |
| HUTCHMED (China) Limited | 436.23 Million USD | 91.025% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 74.598% |
| Akanda Corp. | 3.48 Million USD | -1023.953% |